India’s pharma moving from generics to niche drugs

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

India’s pharma moving from generics to niche drugs

INICIO/Informes | Posted 13/09/2013 0 Post your comment

Indian pharmaceutical companies will increasingly move away from the overcrowded and competitive area of generics and invest more R & D spending in niche drugs, according to a new report.

Indian pharmaceutical firms are expected to spend more on R & D in the near future as they target potentially lucrative and relatively underdeveloped niche therapy area drugs markets.

Indian companies such as Ranbaxy, Dr Reddy’s, Lupin and Wockhardt are cited as examples of generics makers that have already been making moves towards niche drug production, with increasing R & D investments.

The generics sector dominates India’s pharmaceuticals market, however, it does not guarantee long-term profitability or sustainable financial growth. Since there are fewer barriers to market entry for generics compared to brand-name drugs, competition in the generics sector is fierce and profit margins are slim. This could fuel the drive towards niche drugs, despite the higher costs involved.

India’s new drug pricing controls may also not be helping companies to make a profit in the generics sector. India recently introduced a new Drug Price Control Order (DPCO), affecting both brand-name and generic drugs, which is expected to lead to price reductions of up to 80% in ‘essential drugs’ [1]. Although other proposed legislation that would make it compulsory for doctors to prescribe only low cost generic drugs could work in favour of generics companies [2].

The fact that many Indian companies already possess considerable manufacturing capabilities and would be able to leverage their experience and infrastructure into achieving scale economies in the development and production of niche drugs could also ease the transition.

India’s pharmaceutical market value is estimated to increase from US$17 billion in 2012 to US$54 billion by 2020.

References

1. GaBI Online - Generics and Biosimilars Initiative. India introduces new drug pricing control [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Sep 13]. Available from: www.gabionline.net/Policies-Legislation/India-introduces-new-drug-pricing-control

2. GaBI Online - Generics and Biosimilars Initiative. India to make prescribing of generics compulsory [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Sep 13]. Available from: www.gabionline.net/Policies-Legislation/India-to-make-prescribing-of-generics-compulsory

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.